All Stories

  1. Intracellular enzymatic reducing systems control receptor tyrosine kinase signaling via PTP1B
  2. Development of novel analogs of the TRi-1 and TRi-2 selenoprotein thioredoxin reductase inhibitors with initial assessment of their cytotoxicity profiles
  3. Paradoxical effect of anticancer treatment with auranofin
  4. Patient-derived TXNIP-deficient primary cells exhibit NRF2 activation linked to upregulation of glyoxalase 1 (GLO1)
  5. Bicyclic Selenenyl Sulfides with Tuned Bioreductive Step Rates Reveal Constraints for Probes Targeting Thioredoxin Reductase
  6. Bicyclic Selenenyl Sulfides with Tuned Bioreductive Step Rates Reveal Constraints for Probes Targeting Thioredoxin Reductase
  7. Cellular activity of the cytosolic selenoprotein thioredoxin reductase 1 (TXNRD1) is modulated by copper and zinc levels in the cell culture medium
  8. Bicyclic selenenyl sulfides tune stepwise rates of thiol/selenol addition, resolution, and cyclisation, to reveal cellular constraints for bioreductive probes targeting mammalian thioredoxin reductase
  9. Endogenous electrophiles and peroxymonocarbonate can link tyrosine phosphorylation cascades with the cytosolic TXNRD1 selenoprotein and the KEAP1/NRF2 system
  10. TRP14 is the rate-limiting enzyme for intracellular cystine reduction and regulates proteome cysteinylation
  11. Ancient Loss of Catalytic Selenocysteine Spurred Convergent Adaptation in a Mammalian Oxidoreductase
  12. Piperazine-Fused Cyclic Disulfides Unlock High-Performance Bioreductive Probes of Thioredoxins and Bifunctional Reagents for Thiol Redox Biology
  13. Arsenic exposure and increased C-reactive protein are independently associated with lower erythrocyte glutathione peroxidase activity in Bangladeshi children
  14. TXNL1 has dual functions as a redox active thioredoxin-like protein as well as an ATP- and redox-independent chaperone
  15. Clozapine suppresses NADPH oxidase activation, counteracts cytosolic H2O2, and triggers early onset mitochondrial dysfunction during adipogenesis of human liposarcoma SW872 cells
  16. Cardiolipin drives the catalytic activity of GPX4 on membranes: Insights from the R152H mutant
  17. Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4
  18. Novel gold(III)-dithiocarbamate complex targeting bacterial thioredoxin reductase: antimicrobial activity, synergy, toxicity, and mechanistic insights
  19. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1
  20. Side-by-side comparison of recombinant human glutathione peroxidases identifies overlapping substrate specificities for soluble hydroperoxides
  21. Ancient loss of catalytic selenocysteine spurred convergent adaptation in a mammalian oxidoreductase
  22. Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases
  23. Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
  24. Redox regulation of PTPN22 affects the severity of T-cell-dependent autoimmune inflammation
  25. Selective cellular probes for mammalian thioredoxin reductase TrxR1: Rational design of RX1, a modular 1,2-thiaselenane redox probe
  26. Biochemical and structural characterizations of thioredoxin reductase selenoproteins of the parasitic filarial nematodes Brugia malayi and Onchocerca volvulus
  27. Cyclic 5-membered disulfides are not selective substrates of thioredoxin reductase, but are opened nonspecifically
  28. Development of a chemical probe that selectively images the activity of mammalian Thioredoxin Reductase 1
  29. Thioredoxin Reductase Inhibition for Cancer Therapy
  30. Thioredoxin and glutathione reductases
  31. Expressing recombinant selenoproteins using redefinition of a single UAG codon in an RF1-depleted E. coli host strain
  32. Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin
  33. Evaluation of dithiothreitol-oxidizing capacity (DOC) as a serum biomarker for chronic hepatitis B in patients exhibiting normal alanine aminotransferase levels: a pilot study towards better monitoring of disease
  34. Development of therapies for rare genetic disorders of GPX4: roadmap and opportunities
  35. Production and purification of homogenous recombinant human selenoproteins reveals a unique codon skipping event in E. coli and GPX4-specific affinity to bromosulfophthalein
  36. Selective, Modular Probes for Thioredoxins Enabled by Rational Tuning of a Unique Disulfide Structure Motif
  37. In Memoriam Arne Holmgren (1940–2020)
  38. Comment on “Evidence that the ProPerDP method is inadequate for protein persulfidation detection due to lack of specificity”
  39. Development of Therapies for Rare Genetic Disorders of GPX4: Roadmap and Opportunities
  40. Selective, Modular Probes for Thioredoxins Enabled by Rational Tuning of a Unique Disulfide Structure Motif
  41. System-wide identification and prioritization of enzyme substrates by thermal analysis
  42. Qualitative Differences in Protection of PTP1B Activity by the Reductive Trx1 or TRP14 Enzyme Systems upon Oxidative Challenges with Polysulfides or H2O2 Together with Bicarbonate
  43. Molecular Basis for the Interactions of Human Thioredoxins with Their Respective Reductases
  44. To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors
  45. Identification and targeting of selective vulnerability rendered by tamoxifen resistance
  46. Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate
  47. Comprehensive chemical proteomics for target deconvolution of the redox active drug auranofin
  48. Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death
  49. Direct Observation of Methylmercury and Auranofin Binding to Selenocysteine in Thioredoxin Reductase
  50. Characterization of Lead Compounds Targeting the Selenoprotein Thioredoxin Glutathione Reductase for Treatment of Schistosomiasis
  51. Effects of Mammalian Thioredoxin Reductase Inhibitors
  52. Perspectives of TrxR1-based cancer therapies
  53. Inhibition and crosslinking of the selenoprotein thioredoxin reductase-1 by p-benzoquinone
  54. Common modifications of selenocysteine in selenoproteins
  55. Author Correction: Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system
  56. Which Antioxidant System Shapes Intracellular H2O2 Gradients?
  57. Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system
  58. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug
  59. Bicarbonate is essential for protein-tyrosine phosphatase 1B (PTP1B) oxidation and cellular signaling through EGF-triggered phosphorylation cascades
  60. TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy
  61. Absence of TXNIP in Humans Leads to Lactic Acidosis and Low Serum Methionine Linked to Deficient Respiration on Pyruvate
  62. ProPerDP: A Protein Persulfide Detection Protocol
  63. Efficient selenocysteine-dependent reduction of toxoflavin by mammalian thioredoxin reductase
  64. NADPH-dependent and -independent disulfide reductase systems
  65. Selenium and selenoproteins in (redox) signaling, diseases, and animal models - 200 year anniversary issue
  66. Selenium research in biochemistry and biophysics - 200 year anniversary issue
  67. Thioredoxin-related protein of 14 kDa as a modulator of redox signalling pathways
  68. Fragment-Based Discovery of a Regulatory Site in Thioredoxin Glutathione Reductase Acting as “Doorstop” for NADPH Entry
  69. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy
  70. The A to Z of modulated cell patterning by mammalian thioredoxin reductases
  71. Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis
  72. H2O2, Thioredoxin, and Signaling
  73. Overexpression of Recombinant Selenoproteins in E. coli
  74. Selective Evaluation of Thioredoxin Reductase Enzymatic Activities
  75. Time- and cell-resolved dynamics of redox-sensitive Nrf2, HIF and NF-κB activities in 3D spheroids enriched for cancer stem cells
  76. Thioredoxin reductase 1 and NADPH directly protect protein tyrosine phosphatase 1B from inactivation during H 2 O 2 exposure
  77. Molecular Mechanisms of Regulated Cell Pattering by the Mammalian Thioredoxin System
  78. Hepatocyte Hyperproliferation upon Liver-Specific Co-disruption of Thioredoxin-1, Thioredoxin Reductase-1, and Glutathione Reductase
  79. Mark Your Calendar
  80. Homozygous mutation in TXNRD1 is associated with genetic generalized epilepsy
  81. Rutin protects against H 2 O 2 -triggered impaired relaxation of placental arterioles and induces Nrf2-mediated adaptation in Human Umbilical Vein Endothelial Cells exposed to oxidative stress
  82. Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
  83. Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-κB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution
  84. Selenocysteine Insertion at a Predefined UAG Codon in a Release Factor 1 (RF1)-depletedEscherichia coliHost Strain Bypasses Species Barriers in Recombinant Selenoprotein Translation
  85. Mark Your Calendar
  86. Cytosolic thioredoxin reductase 1 is required for correct disulfide formation in the ER
  87. Mark Your Calendar
  88. Targeting the Selenoprotein Thioredoxin Reductase 1 for Anticancer Therapy
  89. Thioredoxin System
  90. Selenium Metabolism in Herbivores and Higher Trophic Levels Including Mammals
  91. Serum thioredoxin reductase is highly increased in mice with hepatocellular carcinoma and its activity is restrained by several mechanisms
  92. Selenoprotein Gene Nomenclature
  93. Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors
  94. Inhibitory nitrosylation of mammalian thioredoxin reductase 1: Molecular characterization and evidence for its functional role in cellular nitroso-redox imbalance
  95. Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake
  96. Thioredoxin reductase 1 suppresses adipocyte differentiation and insulin responsiveness
  97. Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells
  98. Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads
  99. Details in the catalytic mechanism of mammalian thioredoxin reductase 1 revealed using point mutations and juglone-coupled enzyme activities
  100. A novel persulfide detection method reveals protein persulfide- and polysulfide-reducing functions of thioredoxin and glutathione systems
  101. Selenium Research (Se2017)
  102. Mark Your Calendar
  103. Mark Your Calendar
  104. Mark Your Calendar
  105. Paradoxical Roles of Antioxidant Enzymes: Basic Mechanisms and Health Implications
  106. Thioredoxin Reductase 1 as an Anticancer Drug Target
  107. TrxR1 as a Potent Regulator of the Nrf2-Keap1 Response System
  108. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells
  109. Dietary methionine can sustain cytosolic redox homeostasis in the mouse liver
  110. The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death
  111. Serum thioredoxin reductase levels increase in response to chemically induced acute liver injury
  112. Sec-containing TrxR1 is essential for self-sufficiency of cells by control of glucose-derived H2O2
  113. Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase
  114. Redox active motifs in selenoproteins
  115. The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death
  116. Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures
  117. Sepp1UF forms are N-terminal selenoprotein P truncations that have peroxidase activity when coupled with thioredoxin reductase-1
  118. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis
  119. The selenoprotein thioredoxin reductase as a key regulator of cellular signaling pathways
  120. A Txnrd1-dependent metabolic switch alters hepatic lipogenesis, glycogen storage, and detoxification
  121. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
  122. Wobble decoding by the Escherichia coli selenocysteine insertion machinery
  123. Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGF-β receptor tyrosine kinase signaling
  124. Redox activation of Fe(III)–thiosemicarbazones and Fe(III)–bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trapping
  125. BBA General Subjects – Changing of the Guard at the Publishing Palace
  126. Multilevel Regulation of 2-Cys Peroxiredoxin Reaction Cycle byS-Nitrosylation
  127. Site-specifically 11C-labeled Sel-tagged annexin A5 and a size-matched control for dynamic in vivo PET imaging of protein distribution in tissues prior to and after induced cell death
  128. The Rare TXNRD1_v3 (“v3”) Splice Variant of Human Thioredoxin Reductase 1 Protein Is Targeted to Membrane Rafts byN-Acylation and Induces Filopodia Independently of Its Redox Active Site Integrity
  129. Simvastatin inhibits the core promoter of the TXNRD1 gene and lowers cellular TrxR activity in HepG2 cells
  130. Thioredoxin Reductase Inhibition Elicits Nrf2-Mediated Responses in Clara Cells: Implications for Oxidant-Induced Lung Injury
  131. Thiophosphate and selenite conversely modulate cell death induced by glutathione depletion or cisplatin: effects related to activity and Sec contents of thioredoxin reductase
  132. HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically 11C-Labeled Sel-Tagged Affibody Molecule
  133. Combining [11C]-AnxA5 PET Imaging with Serum Biomarkers for Improved Detection in Live Mice of Modest Cell Death in Human Solid Tumor Xenografts
  134. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase
  135. Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1
  136. Biochemical Discrimination between Selenium and Sulfur 2: Mechanistic Investigation of the Selenium Specificity of Human Selenocysteine Lyase
  137. Biochemical Discrimination between Selenium and Sulfur 1: A Single Residue Provides Selenium Specificity to Human Selenocysteine Lyase
  138. Thioredoxin Reductase Inhibition Induces Nrf2mediated Antioxidant Responses in Murine Transformed Clara Cells
  139. Redox Pioneer: Professor Arne Holmgren
  140. Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay
  141. Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors
  142. Selenoprotein TRXR-1 and GSR-1 are essential for removal of old cuticle during molting in Caenorhabditis elegans
  143. History of Selenium Research
  144. Human Protein Atlas of redox systems — What can be learnt?
  145. Noble metal targeting of thioredoxin reductase — covalent complexes with thioredoxin and thioredoxin-related protein of 14kDa triggered by cisplatin
  146. Effects of selenite and chelating agents on mammalian thioredoxin reductase inhibited by mercury: implications for treatment of mercury poisoning
  147. The Selenium-independent Inherent Pro-oxidant NADPH Oxidase Activity of Mammalian Thioredoxin Reductase and Its Selenium-dependent Direct Peroxidase Activities
  148. Selenoproteins—What unique properties can arise with selenocysteine in place of cysteine?
  149. The Interactions of Thioredoxin Reductase with Quinones and Acrolein: Covalent Adducts and Stimulation of NADPH Oxidase Activity
  150. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy
  151. Special issue on selenoprotein expression and function
  152. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA
  153. Structure Mechanism Insights and the Role of Nitric Oxide Donation Guide the Development of Oxadiazole-2-Oxides as Therapeutic Agents against Schistosomiasis
  154. The human thioredoxin reductase-1 splice variant TXNRD1_v3 is an atypical inducer of cytoplasmic filaments and cell membrane filopodia
  155. Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions
  156. Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice
  157. Red wine triggers cell death and thioredoxin reductase inhibition: Effects beyond resveratrol and SIRT1
  158. Highly active dimeric and low-activity tetrameric forms of selenium-containing rat thioredoxin reductase 1
  159. Cisplatin and Oxaliplatin Toxicity: Importance of Cochlear Kinetics as a Determinant for Ototoxicity
  160. Crystal Structure and Catalysis of the Selenoprotein Thioredoxin Reductase 1
  161. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation
  162. Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates
  163. Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells
  164. Induction of Cell Membrane Protrusions by the N-terminal Glutaredoxin Domain of a Rare Splice Variant of Human Thioredoxin Reductase 1
  165. Correction: Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target
  166. Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target
  167. Differential regulation of expression of cytosolic and mitochondrial thioredoxin reductase in rat liver and kidney
  168. The thioredoxin system in cancer
  169. The thioredoxin system in cancer—introduction to a thematic volume of Seminars in Cancer Biology
  170. Titration and Conditional Knockdown of the prfB Gene in Escherichia coli: Effects on Growth and Overproduction of the Recombinant Mammalian Selenoprotein Thioredoxin Reductase
  171. Selenolthiol and Dithiol C-Terminal Tetrapeptide Motifs for One-Step Purification and Labeling of Recombinant Proteins Produced in E. coli
  172. Studies of an active site mutant of the selenoprotein thioredoxin reductase: The Ser-Cys-Cys-Ser motif of the insect orthologue is not sufficient to replace the Cys-Sec dyad in the mammalian enzyme
  173. Tagging recombinant proteins with a Sel-tag for purification, labeling with electrophilic compounds or radiolabeling with 11C
  174. Interactions of Nitroaromatic Compounds with the Mammalian Selenoprotein Thioredoxin Reductase and the Relation to Induction of Apoptosis in Human Cancer Cells
  175. Selenocysteine in proteins—properties and biotechnological use
  176. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds
  177. Thioredoxin reductase 1
  178. A mouse model for in vivo tracking of the major dust mite allergen Der p 2 after inhalation
  179. Overexpression of Enzymatically Active Human Cytosolic and Mitochondrial Thioredoxin Reductase in HEK-293 Cells
  180. Exploiting the 21st amino acid—purifying and labeling proteins by selenolate targeting
  181. Assessment of Production Conditions for Efficient Use of Escherichia coli in High-Yield Heterologous Recombinant Selenoprotein Synthesis
  182. Expression of selenocysteine-containing glutathione S-transferase in Escherichia coli
  183. Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins
  184. Evidence for intriguingly complex transcription of human thioredoxin reductase 1
  185. Regulation of the Mammalian Selenoprotein Thioredoxin Reductase 1 in Relation to Cellular Phenotype, Growth, and Signaling Events
  186. Interactions of Quinones with Thioredoxin Reductase
  187. Active sites of thioredoxin reductases: Why selenoproteins?
  188. Selenocysteine Insertion and Reactivity: Mammalian Thioredoxin Reductases in Relation to Cellular Redox Signaling
  189. Rapid Induction of Cell Death by Selenium-compromised Thioredoxin Reductase 1 but Not by the Fully Active Enzyme Containing Selenocysteine
  190. Regeneration of the antioxidant ubiquinol by lipoamide dehydrogenase, thioredoxin reductase and glutathione reductase
  191. The Mammalian Cytosolic Selenoenzyme Thioredoxin Reductase Reduces Ubiquinone
  192. Recombinant Expression of Mammalian Selenocysteine-Containing Thioredoxin Reductase and Other Selenoproteins in Escherichia coli
  193. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system1 1This review is based on the licentiate thesis “Thioredoxin reductase—interactions with the redox active compounds 1-chloro-2,4-dinitrobenzene and lipoic acid” by Jonas Nordbe...
  194. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis -diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex
  195. The Core Promoter of Human Thioredoxin Reductase 1
  196. Measurement of Thioredoxin and Thioredoxin Reductase
  197. Physiological functions of thioredoxin and thioredoxin reductase
  198. Truncated Thioredoxin Is a Mitogenic Cytokine for Resting Human Peripheral Blood Mononuclear Cells and Is Present in Human Plasma
  199. Structure and mechanism of mammalian thioredoxin reductase: The active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence
  200. Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5′ untranslated region
  201. Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5′ untranslated region
  202. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA , selB and selC genes 1 1Edited by M. Gottesman
  203. Preparation and assay of mammalian thioredoxin and thioredoxin reductase
  204. Superoxide production by dinitrophenyl- derivatized thioredoxin reductase - a model for the mechanism and correlation to immunostimulation by dinitrohalobenzenes
  205. Mammalian Thioredoxin Reductase Is Irreversibly Inhibited by Dinitrohalobenzenes by Alkylation of Both the Redox Active Selenocysteine and Its Neighboring Cysteine Residue
  206. Rat and Calf Thioredoxin Reductase Are Homologous to Glutathione Reductase with a Carboxyl-terminal Elongation Containing a Conserved Catalytically Active Penultimate Selenocysteine Residue
  207. Efficient Reduction of Lipoamide and Lipoic Acid by Mammalian Thioredoxin Reductase
  208. On the Phosphorylation of 2-chlorodeoxy-adenosine (CdA) and Its Correlation with Clinical Response in Leukemia Treatment
  209. 1-Chloro-2,4-dinitrobenzene Is an Irreversible Inhibitor of Human Thioredoxin Reductase
  210. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues
  211. Mammalian deoxyribonucleoside kinases
  212. Mitochondrial Versus Cytosolic Activities of Deoxyribonucleoside Salvage Enzymes
  213. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients
  214. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy
  215. Deoxycytidine and 2′,3′-Dideoxycytidine Metabolism in Human Monocyte-Derived Macrophages: A Study of Both Anabolic and Catabolic Pathways
  216. Catabolism of Deoxycytidine in Human Peripheral Blood Mononuclear Cells and Its Interference with the Determination of in Situ Thymidylate Synthase Activity
  217. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues
  218. Deoxycytidine kinase is constitutively expressed in human lymphocytes: Consequences for compartmentation effects, unscheduled dna synthesis, and viral replication in resting cells
  219. Maximal flux responses after multiple challenges with vasopressin
  220. Biotechnology of selenocysteine
  221. Thioredoxin System